EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets

Astrid I P Vernemmen, Iryna V Samarska iD, Ernst-Jan M Speel, Robert G Riedl, Danny Goudkade, Adriaan P de Bruïne, Siep Wouda, Arienne M van Marion, Ivana V Verlinden, Ineke van Lijnschoten, Pieter Friederich, Véronique J L Winnepenninckx und 3 weitere

Histopathology · 2024-04 · 84 (5) · 794-809

DOI: 10.1111/his.15122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, online erschienen am 28.12.2023. Verfasst von Astrid I P Vernemmen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Sarcoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Inflammatory myofibroblastic tumour (IMT) is a rare mesenchymal neoplasm of intermediate malignant potential, occurring at any age and at multiple sites. Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an aggressive subtype of IMT, typically involving the abdomen. Most IMTs harbour kinase gene fusions, especially involving ALK and ROS1 , but 20–30% of IMTs show no detectable translocations. The aim of this study is to further delineate clinicopathological and molecular characteristics of abdominal IMT and discover potential new therapeutic targets. Methods and results In 20 IMTs, including four EIMS, RNA fusion analysis was performed, followed by multiplex DNA analysis if no ALK or ROS1 fusion was detected. Fourteen IMTs (70.0%) had an ALK translocation and the fusion partner was identified in 11, including a RRBP1::ALK fusion, not previously described in classical (non‐EIMS) IMT. RANBP2::ALK fusion was demonstrated in all EIMS. One IMT had a ROS1 fusion. In all ALK/ROS1 translocation‐negative IMTs mutations or fusions – as yet unreported in primary IMT – were found in genes related to the receptor tyrosine kinase (RTK)/PI3K/AKT pathway. Three of four patients with EIMS died of disease [mean survival 8 months (4–15 months)], whereas only one of 14 classical IMT patients succumbed to disease [mean follow‐up time 52 months (2–204 months); P < 0.01].

Conclusion

This study shows the wide clinical spectrum of abdominal IMTs and affirms the poor prognosis of EIMS, raising discussion about its status as IMT subtype. Furthermore, the newly detected alterations of the RTK/PI3K/AKT pathway expand the molecular landscape of IMTs and provide potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesSarcomaHumansAnaplastic Lymphoma KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

epithelioid inflammatory myofibroblastic sarcomainflammatory myofibroblastic tumourkinase fusionmolecular diagnosticstargeted therapy

Substanzen

Anaplastic Lymphoma KinaseProtein-Tyrosine KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, Maastricht, The Netherlands.
  • Department of Pathology, Zuyderland Medical Center, Geleen, The Netherlands.
  • Department of Pathology, VieCuri Medical Center, Venlo, The Netherlands.
  • Department of Pathology, Laurentius Hospital, Roermond, The Netherlands.
  • Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, The Netherlands.
  • Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands.

ORCID-Profile: Iryna V Samarska, Raf M E Sciot, Mari F C M van den Hout

Zitieren

APA

Vernemmen, A. I. P., Samarska, I. V., Speel, E. M., Riedl, R. G., Goudkade, D., de Bruïne, A. P., Wouda, S., van Marion, A. M., Verlinden, I. V., van Lijnschoten, I., Friederich, P., Winnepenninckx, V. J. L., Zur Hausen, A., Sciot, R. M. E., & van den Hout, M. F. C. M. (2024). Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets. Histopathology, 84(5), 794-809. https://doi.org/10.1111/his.15122

Vancouver

Vernemmen AIP, Samarska IV, Speel EM, Riedl RG, Goudkade D, de Bruïne AP, et al. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets. Histopathology. 2024;84(5):794-809. doi:10.1111/his.15122

BibTeX
@article{Vernemmen2024,
  author = {Vernemmen, Astrid I P and Samarska, Iryna V and Speel, Ernst-Jan M and Riedl, Robert G and Goudkade, Danny and de Bruïne, Adriaan P and Wouda, Siep and van Marion, Arienne M and Verlinden, Ivana V and van Lijnschoten, Ineke and Friederich, Pieter and Winnepenninckx, Véronique J L and Zur Hausen, Axel and Sciot, Raf M E and van den Hout, Mari F C M},
  title = {Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets},
  journal = {Histopathology},
  year = {2024},
  volume = {84},
  number = {5},
  pages = {794--809},
  doi = {10.1111/his.15122}
}
Kostenlos starten →